207 related articles for article (PubMed ID: 9597800)
101. Use of genetic markers in multiple myeloma.
Fonseca R
Clin Adv Hematol Oncol; 2017 Jun; 15(6):446-448. PubMed ID: 28749904
[No Abstract] [Full Text] [Related]
102. [HLA markers in myeloma and benign monoclonal dysglobulinemias].
Cassuto JP; Piereschi J; Maiolini R; Dujardin P; Ribeil R; Masseyeff R
Nouv Presse Med; 1981 Jan; 10(4):252-3. PubMed ID: 7465363
[No Abstract] [Full Text] [Related]
103. Anaplastic multiple myeloma with MYC rearrangement.
Ichikawa S; Fukuhara N; Hashimoto K; Fujishima F; Ichinohasama R; Harigae H
Leuk Res Rep; 2022; 17():100288. PubMed ID: 35024332
[TBL] [Abstract][Full Text] [Related]
104. Myeloma: new aspects of biology, prognosis and treatment.
Joshua DE
Pathology; 1996 Jan; 28(1):2-7. PubMed ID: 8714260
[No Abstract] [Full Text] [Related]
105. Guest editorial: basic and clinical updates in multiple myeloma.
Kizaki M
Int J Hematol; 2013 Mar; 97(3):304-5. PubMed ID: 23420182
[No Abstract] [Full Text] [Related]
106. Disease and Symptom Care: A Focus on Specific Needs of Patients With Multiple Myeloma.
Faiman B
Clin J Oncol Nurs; 2017 Oct; 21(5 Suppl):3-6. PubMed ID: 28945733
[TBL] [Abstract][Full Text] [Related]
107. [Multiple myeloma of long-term survival. Apropos of a case].
Benabdeljlil M; Aouni M; Mohattane A; Adnaoui M; Maaouni A; Berbich A
Rev Med Interne; 1996; 17(8):703-5. PubMed ID: 8881204
[No Abstract] [Full Text] [Related]
108. Multiple myeloma.
Nurs Stand; 2014 Jun; 28(39):18. PubMed ID: 24866646
[No Abstract] [Full Text] [Related]
109. Role of calcitonin in osteosclerosis of myeloma?
Rousseau JJ; Heynen G; Franck G
Arch Intern Med; 1980 Nov; 140(11):1554. PubMed ID: 7436658
[No Abstract] [Full Text] [Related]
110. [Recent topics in biology of multiple myeloma].
Hattori Y
Rinsho Ketsueki; 2013 Aug; 54(8):692-5. PubMed ID: 24005423
[No Abstract] [Full Text] [Related]
111. Multiple myeloma.
Zulian GB; Babare R; Zagonel V
Crit Rev Oncol Hematol; 1998 Feb; 27(2):165-7. PubMed ID: 9571324
[No Abstract] [Full Text] [Related]
112. Working the magic.
Wallis L
Nurs Stand; 2012 Jun 6-12; 26(40):61. PubMed ID: 22848973
[No Abstract] [Full Text] [Related]
113. Myc is also the bad guy in myeloma.
Manasanch EE
Leuk Lymphoma; 2016 Nov; 57(11):2485-6. PubMed ID: 27676421
[No Abstract] [Full Text] [Related]
114. RAS mutations - for better or for worse in multiple myeloma?
Leich E; Steinbrunn T
Leuk Lymphoma; 2016; 57(1):8-9. PubMed ID: 26430811
[No Abstract] [Full Text] [Related]
115. p53 mutations in multiple myeloma.
Paydaś S; Sahin B; Seyrek E; Zorludemir S
Mol Pathol; 1997 Dec; 50(6):329. PubMed ID: 9536285
[No Abstract] [Full Text] [Related]
116. [Current status and challenges in the treatment of multiple myeloma in China].
Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):281-2. PubMed ID: 23668190
[No Abstract] [Full Text] [Related]
117. [Molecular biology of multiple myeloma: introduction].
Nihon Rinsho; 2016 Jul; 74 Suppl 5():87-91. PubMed ID: 30615312
[No Abstract] [Full Text] [Related]
118. SNPs and PROs in myeloma: the most ambitious crossover of all time?
Banerjee R; Shah N
Bone Marrow Transplant; 2022 Oct; 57(10):1475-1476. PubMed ID: 35768572
[No Abstract] [Full Text] [Related]
119. Extraordinary Progress in the Treatment of Multiple Myeloma: Is a Cure on the Horizon?
Bergsagel PL
Hematol Oncol Clin North Am; 2024 Apr; 38(2):xiii-xv. PubMed ID: 38171938
[No Abstract] [Full Text] [Related]
120. Myeloma and related disorders.
Clin Haematol; 1982 Feb; 11(1):1-238. PubMed ID: 7075038
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
